Table 1.
Gene Name | Gene Ontology Molecular Function | mRNA Expression Profile
|
Functional Validation
|
|||
---|---|---|---|---|---|---|
Vascular Selectivity | Pref. Vasc. Bed | Pref. Stage | cdh5 ISH | FITC-Dextran | ||
alox5ap | Enzyme activator activity | Yes | Skin | - | 0% | 48% |
| ||||||
ctsz | Cysteine-type peptidase activity | Yes | - | - | 12% | 19% |
| ||||||
fzd6 | G protein-coupled receptor activity | Yes | - | - | 21% | 55% |
| ||||||
gnb2l1 | GTPase activity | Yes | - | Embryo | 12% | 49% |
| ||||||
hexb | β-N-acetylhexosaminidase activity | Yes | Brain | Adult | 28% | 58% |
| ||||||
kiaa1274 | Protein tyrosine phosphatase activity | Yes | Brain | Embryo | 10% | 53% |
| ||||||
p2ry5 | Purinergic receptor activity, G protein coupled | Yes | Skin | Adult | 20% | 24% |
| ||||||
ppap2a | Phosphatidate phosphatase activity | Yes | - | Adult | 48% | 57% |
| ||||||
ppih | Cyclosporin A binding | Yes | Heart | Embryo | 3% | 82% |
| ||||||
ppp1ca | Protein Ser/Thr phosphatase activity | Yes | - | Embryo | 0% | 81% |
| ||||||
ppp1cc | Protein Ser/Thr phosphatase activity | No | Brain | - | 32% | 44% |
| ||||||
ppp4c | Protein Ser/Thr phosphatase activity | Yes | Heart | Embryo | 18% | 28% |
| ||||||
rab11a | GTPase activity | Yes | Heart | Adult | 0% | 32% |
| ||||||
rab5c | GTPase activity | Yes | Skin | - | 0% | 54% |
| ||||||
ralb | GTP binding | Yes | - | Embryo | 12% | 84% |
| ||||||
sat1 | Diamine N-acetyltransferase activity | Yes | Heart | Embryo | 0% | 43% |
All gene names are for human genes. Vascular selectivity was defined as “Yes” or “No,” where “Yes” corresponded to upregulated (p < 0.05) signal in one or more comparisons of vascular fragments against nonvascular tissues, and “No” corresponded to nonregulated signal in one or more comparisons of vascular fragments against nonvascular tissues. Preferentially enriched expression in a vascular bed (Pref. Vasc. Bed) was defined as upregulated (p < 0.05) signal in one vascular bed compared to another vascular bed. Significantly higher expression of a gene at embryonic or adult stages was indicated as either preferred “Embryo” or “Adult.” The underlying data are presented in Table S2. cdh5 ISH, the percentage of zebrafish embryos with aberrant cdh5 expression in the intersegmental vessels at 48–56 hpf, as detected by in situ hybridization. FITC-Dextran, the percentage of zebrafish embryos with defective intersegmental vessels evident by FITC-dextran microangiography at 48–56 hpf. Details of reduced cdh5 staining and/or FITC-dextran labeling are shown in Figure S4.